anti-CD3/anti-Trop2/anti-CDH17S trispecific T-cell engager (Boehringer Ingelheim)

N/A

Report date: 2026/03/19 16:53:20

Base Information

Drug Nameanti-CD3/anti-Trop2/anti-CDH17S trispecific T-cell engager (Boehringer Ingelheim)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsTumor-associated calcium signal transducer 2 modulatorsT lymphocytes stimulants +[5] 
TargetsCadherin-17Tumor-associated calcium signal transducer 2T cell surface glycoprotein CD3
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim International Gmbh
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsColorectal Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A